Skip to Content
Merck
  • Involvement of the receptor-associated prorenin system in the pathogenesis of human conjunctival lymphoma.

Involvement of the receptor-associated prorenin system in the pathogenesis of human conjunctival lymphoma.

Investigative ophthalmology & visual science (2014-12-17)
Erdal Tan Ishizuka, Atsuhiro Kanda, Satoru Kase, Kousuke Noda, Susumu Ishida
ABSTRACT

Extranodal marginal zone B-cell lymphoma (EMZL) is the most common subtype of conjunctival lymphoma, though its molecular mechanisms of pathogenesis are largely unknown. We attempted to explore the association of the renin-angiotensin system (RAS) and (pro)renin receptor ([P]RR) in the pathogenesis of conjunctival lymphoma. Surgically removed conjunctiva EMZL samples were used for gene expression, and immunohistochemical and immunofluorescence analyses of (P)RR and RAS components. Human B-lymphoblast IM-9 cells were treated with prorenin or angiotensin II (Ang II), and gene expression levels were analyzed using real-time quantitative PCR (qPCR). In addition, immunofluorescence analysis of EMZL samples was used to evaluate the in vivo expression of those components. Gene expression and immunohistochemical analyses revealed the expression of RAS components, including (P)RR and angiotensin II type 1 receptor (AT1R), in EMZL tissues. Double-labeling analyses demonstrated that (P)RR and AT1R were detected in cells positive for CD20, a marker for B-cells, where they colocalized with prorenin and angiotensinogen, respectively. Prorenin stimulation of human B-lymphoblast IM-9 cells increased mRNA expression levels of fibroblast growth factor 2 (FGF2), while angiotensin II treatment upregulated the expression levels of basigin (BSG), matrix metallopeptidase (MMP)2, 9, and 14, which were abolished by (P)RR and AT1R blockades, respectively. Immunofluorescence analyses of clinical samples showed colocalizations of (P)RR and AT1R with the products of these upregulated genes. The present study suggests that activation of (P)RR and AT1R is associated with the pathogenesis of conjunctival EMZL by stimulating the production of FGF2 and MMPs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Valsartan, ≥98% (HPLC)
Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Valsartan, United States Pharmacopeia (USP) Reference Standard
Valsartan, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Adenosine 5′-Triphosphatase from porcine cerebral cortex, lyophilized powder, ≥0.3 units/mg protein, pH 7.8
Supelco
Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material
Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard